InsideOutBio

InsideOutBio is developing a novel class of Programmable Therapeutics™(PTx) for cancer therapy engineered to ‘light’ up tumors for the immune system to destroy. The treatment aims to protect against a relapse by inducing long-term immunity. Our initial focus is on Renal and Ovarian Cancer because of the huge unmet patient need Patients often present with late stage disease and are usually treated with chemotherapy. Morbidity is high and survival is poor. PTx's act within tumor cells turning-on immune-stimulatory pathways while turning-off other mechanisms that suppress the immune response. They attack the command and control systems essential to the tumor’s survival. By throwing pathway switches, PTx's take tumors out of stealth mode, rendering them visible to the immune system. Once activated, immune cells destroy tumors throughout the body. Our approach complements existing immuno-therapies that work best on ‘hot’ tumors. Since only 10-20% of cancers are ‘hot’ when first diagnosed, by making ‘cold’ tumors ‘hot’ our approach will make existing immune-therapies more effective. Our primary market are patients in the initial phase of tumor treatment. Currently chemotherapy is used to induce remission from cancer. Our goal is to replace chemotherapy with a less toxic intervention and deliver better overall outcomes. InsideOutBio is developing IP covering methods to target the Programmable Therapeutics™(PTx) inside tumor cells and for a novel 3rd generation viral therapeutic built from a catalog of independently validated parts using an assembly line process. Our methods for re-engineering pathways inside tumors is general and can be applied to other indications.